Imugene (ASX: IMU) Share Price and News

Ms Chong joined the Group in September 2015 from the oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 25 years of experience in clinical and department development in oncology.

Mr Hopper has over 20 years of experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered several therapeutic areas with a particular emphasis on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States.

Mr Kotsanis brings 35 years operational leadership experience in global pharmaceutical markets, leading regional franchises at Hospira/Mayne Pharma (oncology injectables, US$500M plus EMEA revenue) and Synthon (generics/biologics), driving commercialisation, licensing and market expansion. He returned to Australia in 2014 to assume the CEO position at Acrux (ASX:ACR), directing pipeline development, business development, capital management/investor relations, and ASX/ASIC compliance for a topical pharmaceutical product developer. Throughout his career he has held Executive Director appointments on the main Board of Synthon (private) and operating subsidiaries of the listed companies. Michael is a Non-Executive Director at ICE Pharma, a private equity owned, Italian pharmaceutical company that manufactures pharmaceutical ingredients. He was formerly a Non-Executive Director at IDT Australia (ASX:IDT) where he was also Chair of the Human Capital/Remuneration Committee and an Audit/Risk Committee member.

Dr Russell is a haematologist/oncologist and has over 25 years of experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in several therapeutic areas including haematology/oncology and has had multiple new drug approvals with both FDA and European Medicines Agency. Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a Member of the Risk Committee.

Dr Gittleson is a biopharmaceutical senior executive with over 20 years of global experience in drug development, clinical strategy, and regulatory affairs. She served as Chief Medical Officer at CSL Limited, where she led global clinical and medical governance across a portfolio of therapies, including rare diseases, immunology, and vaccines. Her leadership was in advancing CSL's innovation pipeline and navigating global regulatory environments. Since transitioning from executive leadership, Charmaine has held Non-Executive roles within a number of ASX-listed life sciences companies, mainly focused on oncology. She is currently Chair of Percheron Therapeutics (ASX:PER) and is a Non-Executive Director of PolyNovo (ASX:PNV) and George Medicines. She was previously on the Board of Patrys (ASX:PAB), providing strategic oversight on clinical development, regulatory strategy, and commercial growth.

Dr Dupont is an industry and drug development expert with more than 20 years of experience specialising in oncology and other therapeutic areas. Dr Dupont is currently the Executive Venture Partner at Sofinnova Investments. Dr Dupont's experience includes NASDAQ listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversaw all research and development, including three clinical stage programs spanning Phase 1 through to Phase 3, and numerous preclinical programs. He is a Member of the Risk Committee.

Ms Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. In addition to Imugene, Ms Drapkin currently serves on the board of directors at Acumen Pharmaceuticals (NASDAQ: ABOS) where she chairs the audit committee and is a member of the compensation committee and LENZ Therapeutics (NASDAQ: LENZ) where she is a member of the compensation and governance committees. Most recently, Ms Drapkin was CEO and a board member at Graphite Bio where she led the strategic alternatives process. Prior to that, Ms Drapkin was CFO at Jounce Therapeutics since its inception, playing a key role in building Jounce's financial infrastructure. She is Chair of the Risk Committee.

-

-

-

-

-